The following section summarizes insights on Stoke Therapeutics Inc's EV / EBIT:
March 31, 2025: -
Performance Summary
Stoke Therapeutics's latest twelve months ev / ebit is -1.5x
Stoke Therapeutics's ev / ebit for fiscal years ending December 2020 to 2024 averaged -10.6x.
Stoke Therapeutics's operated at median ev / ebit of -1.5x from fiscal years ending December 2020 to 2024.
Looking back at the last 5 years, Stoke Therapeutics's ev / ebit peaked in December 2023 at -0.2x.
Stoke Therapeutics's ev / ebit hit its 5-year low in December 2020 of -41.5x.
Stoke Therapeutics's ev / ebit decreased in 2020 (-41.5x, +74.3%) and 2024 (-1.5x, +598.5%) and increased in 2021 (-8.6x, -79.4%), 2022 (-1.2x, -86.5%) and 2023 (-0.2x, -82.0%).
Metrics similar to EV / EBIT in the valuation category include:
Damodaran's Industry Cost of Debt - A general benchmark for the cost of debt in an industry based on research by Professor Damodaran at New York University, Stern.
Press space bar to start a drag.
When dragging you can use the arrow keys to move the item around and escape to cancel.
Some screen readers may require you to be in focus mode or to use your pass through key